--Data from landmark VISTA trial accepted for review--
Cambridge, Mass., September 2, 2009 – Millennium: The Takeda Oncology Company today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s supplemental new drug application (sNDA) based on long- term overall survival (OS) data from the landmark VISTA trial examining the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM).
This multicenter, international Phase III clinical trial compared VELCADE in combination with melphalan and prednisone (VcMP) versus melphalan and prednisone (MP) alone in patients with previously untreated MM who were not eligible for stem cell transplantation. In VISTA, the VcMP arm demonstrated a statistically significant improvement in all efficacy endpoints, including time-to-tumor progression, complete response, overall response, progression-free survival, and OS compared to the MP arm.
Due to strong, positive, VISTA trial results in June 2008, FDA approved VELCADE in combination for use with previously untreated MM patients.
“This is the largest Phase III registration study to report long-term overall survival in previously untreated multiple myeloma patients,” said Nancy Simonian, M.D., Chief Medical Officer, Millennium. “This submission of data from the pre-planned long-term survival assessment represents an important milestone in the development of VELCADE.”
VISTA long-term OS data are expected to be presented at a forthcoming scientific conference. VISTA was conducted by Ortho Biotech Oncology Research & Development, a unit of Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (JJPRD) in collaboration with Millennium.
About Multiple Myeloma
Multiple myeloma is the second most common hematologic malignancy and although the disease is predominantly a cancer of the elderly (the median age of onset is 70 years), recent statistics indicate both increasing incidence and younger age of onset. In the U.S., more than 50,000 individuals have MM and 20,000 new cases are diagnosed each year. Worldwide there are approximately 74,000 new cases and over 45,000 deaths annually.
About VISTA
The international Phase III VISTA trial was conducted by Millennium and its co-development partner JJPRD. The trial randomized 682 patients with newly diagnosed multiple myeloma, ineligible for stem cell transplantation, to receive either VELCADE, melphalan and prednisone (VcMP) or melphalan and prednisone (MP) alone,. The primary endpoint of the trial was time-to-disease progression, with secondary endpoints including overall survival, progression-free survival, response rates, and safety. Results include:
· Time-to-disease progression (TTP) in the VcMP arm was 21 months compared to 15 months in the MP arm (p=0.000002).
· Complete response (CR) rate (using EMBT criteria) of 30 percent in the VcMP arm compared to 4 percent in the MP arm.
· VcMP demonstrated statistical significance in overall survival with a 39 percent reduction in risk of death (p=0.00782); median survival was not reached at initial analysis due a short follow-up of 16 months. These survival data are updated in the sNDA filing.
About VELCADE
VELCADE is co-developed by Millennium Pharmaceuticals, Inc. and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Millennium is responsible for commercialization of VELCADE in the U.S., Janssen-Cilag is responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for commercialization in Japan. VELCADE is approved in more than 87 countries worldwide.
Important Safety Information
In the U.S., VELCADE is indicated for the treatment of patients with multiple myeloma. VELCADE also is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron or mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of antineoplastic therapy.
Risks associated with VELCADE therapy include new or worsening peripheral neuropathy, hypotension throughout therapy, cardiac and pulmonary disorders, reversible posterior leukoencephalopathy syndrome, gastrointestinal adverse events, thrombocytopenia, neutropenia, tumor lysis syndrome and hepatic events. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Nursing mothers are advised not to breastfeed while receiving VELCADE. Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. Acute development or exacerbation of congestive heart failure, and new onset of decreased left ventricular ejection fraction has been reported, including reports in patients with no risk factors for decreased left ventricular ejection fraction. There have been reports of acute diffuse infiltrative pulmonary disease of unknown etiology such as pneumonitis, interstitial pneumonia, lung infiltration and Acute Respiratory Distress Syndrome in patients receiving VELCADE. Some of these events have been fatal. There have been reports of Reversible Posterior Leukoencephalopathy Syndrome (RPLS) in patients receiving VELCADE. RPLS is a rare, reversible, neurological disorder which can present with seizure, hypertension, headache, lethargy, confusion, blindness, and other visual and neurological disturbances. VELCADE is associated with thrombocytopenia and neutropenia. There have been reports of gastrointestinal and intracerebral hemorrhage in association with VELCADE. Transfusions may be considered. Complete blood counts (CBC) should be frequently monitored during treatment with VELCADE. Cases of acute liver failure have been reported in patients receiving multiple concomitant medications and with serious underlying medical conditions. Patients who are concomitantly receiving VELCADE and drugs that are inhibitors or inducers of cytochrome P450 3A4 should be closely monitored for either toxicities or reduced efficacy. Patients on oral antidiabetic medication while receiving VELCADE should check blood sugar levels frequently.
Adverse Reaction Data
Safety data from Phase II and III studies of single-agent VELCADE 1.3 mg/m2/dose twice weekly for 2 weeks followed by a 10-day rest period in 1163 patients with previously treated multiple myeloma (N=1008, not including the Phase III, VELCADE plus DOXIL® [doxorubicin HCl liposome injection] study) and previously treated mantle cell lymphoma (N=155) were integrated and tabulated. In these studies, the safety profile of VELCADE was similar in patients with multiple myeloma and mantle cell lymphoma.
In the integrated analysis, the most commonly reported adverse events were asthenic conditions (including fatigue, malaise and weakness) (64%), nausea (55%), diarrhea (52%), constipation (41%), peripheral neuropathy NEC (including peripheral sensory neuropathy and peripheral neuropathy aggravated) (39%), thrombocytopenia and appetite decreased (including anorexia) (each 36%), pyrexia (34%), vomiting (33%), anemia (29%), edema (23%), headache, paresthesia and dysesthesia and headache (each 22%), dyspnea (21%), cough and insomnia (each 20%), rash (18%), arthralgia (17%), neutropenia and dizziness (excluding vertigo) (each 17%), pain in limb and abdominal pain (each 15%), bone pain (14%), back pain and hypotension (each 13%), herpes zoster, nasopharyngitis, upper respiratory tract infection, myalgia and pneumonia (each 12%), muscle cramps (11%), and dehydration and anxiety (each 10%). Twenty percent (20%) of patients experienced at least 1 episode of ≥Grade 4 toxicity, most commonly thrombocytopenia (5%) and neutropenia (3%). A total of 50% of patients experienced serious adverse events (SAEs) during the studies. The most commonly reported SAEs included pneumonia (7%), pyrexia (6%), diarrhea (5%), vomiting (4%), and nausea, dehydration, dyspnea and thrombocytopenia (each 3%).
In the Phase 3 VELCADE + melphalan and prednisone study, the safety profile of VELCADE in combination with melphalan/prednisone is consistent with the known safety profiles of both VELCADE and melphalan/prednisone. The most commonly reported adverse events for VELCADE in combination with MP vs MP, respectively, were thrombocytopenia (52% vs 47%), neutropenia (49% vs 46%), nausea (48% vs 28%), peripheral neuropathy (47% vs 5%), diarrhea (46% vs 17%), anemia (43% vs 55%), constipation (37% vs 16%), neuralgia (36% vs 1%), leukopenia (33% vs 30%), vomiting (33% vs 16%), pyrexia (29% vs 19%), fatigue (29% vs 26%), lymphopenia (24% vs 17%), anorexia (23% vs 10%), asthenia (21% vs 18%), cough (21% vs 13%), insomnia (20% vs 13%), edema peripheral (20% vs 10%), rash (19% vs 7%), back pain (17% vs 18%), pneumonia (16% vs 11%), dizziness (16% vs 11%), dyspnea (15% vs 13%), headache (14% vs 10%), pain in extremity (14% vs 9%), abdominal pain (14% vs 7%), paresthesia (13% vs 4%), herpes zoster (13% vs 4%), bronchitis (13% vs 8%), hypokalemia (13% vs 7%), hypertension (13% vs 7%), abdominal pain upper (12% vs 9%), hypotension (12% vs 3%), dyspepsia (11% vs 7%), nasopharyngitis (11% vs 8%), bone pain (11% vs 10%), arthralgia (11% vs 15%) and pruritus (10% vs 5%).
About Millennium
Millennium: The Takeda Oncology Company, a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE® (bortezomib) for Injection, a first-in-class proteasome inhibitor, and has a robust clinical development pipeline of product candidates. Millennium Pharmaceuticals, Inc. was acquired by Takeda Pharmaceutical Company Ltd. in May, 2008. The Company’s research, development and commercialization activities are focused in oncology. Additional information about Millennium is available through its website, www.millennium.com.
Contacts:
Karen Gobler
617-444-1392
Karen.Gobler@mpi.com
Manisha Pai
617-551-7877
Manisha.Pai@mpi.com
Photo: Millennium Thank you card to Patients
YOU ARE LEAVING MILLENNIUM.COM
You are now leaving www.millennium.com. Links to sites outside of Millennium are provided as a resource to the viewer. Millennium accepts no responsibility for the linked sites that Millennium has no control over.
To stay on the current Web site, click "Cancel."
ContinueCancel
Read our social media guidelines below
INTERACTING WITH MILLENNIUM ON SOCIAL MEDIA
Mission
Our mission is to deliver extraordinary medicines to patients with cancer worldwide through our science, innovation, and passion. We recognize the changing communication ecosystem and value our interaction with patients, caregivers, healthcare professionals and anyone else who is interested in learning about our fight against cancer.
As a leading oncology biopharmaceutical organization we hold ourselves to the highest ethical, legal, and regulatory standards unique to this industry. Millennium has established a presence on select channels to engage audiences in a way that meets our objectives of joining in the conversation that social media enables, while responsibly communicating with the public. To do so, we have developed a set of guidelines to better help our followers understand the unique parameters of how we will utilize these platforms.
Definition of Social Media
For our purposes, social media are online services where users can interact with one another. Millennium chooses to participate in some, but not all, of these services. Current channels in which Millennium participates:
Other services may be added. Check back occasionally to see all of the channels we support.
Comments and Other User-Generated Content
Many of the channels in which we participate allow for comments and other additions by members of the public. Examples of topics that we encourage include posts you approve of, ways we can improve our posts, and suggestions for other topics you would like to see.
Comments on our social media properties are welcome; however, we are required by law to moderate all comments to ensure we stay within government regulations. Comments are moderated for adherence to our terms and conditions posted on each channel, which state:
In scenarios when Millennium cannot post or must remove your comment, we will attempt to send a private message to you explaining why. Otherwise, have at it. Millennium wants to hear from you about our work in the fight against cancer.
References to Millennium from Your Own Property
Often social media channels will allow you to link to or reference a Millennium social media account. We welcome this interaction, however, we will not respond to inflammatory posts, hateful attacks on Millennium or other social media channel users, or obscene language. The topic restrictions listed above apply to posts that mention us, and we cannot reply to any that violate our terms and conditions. Unlike comments on our own properties, we will not attempt to contact someone who mentions us in violation of the above.
We will do our best to answer your comments and questions; however, there may be some things we cannot address, such as questions directly related to financial, legal, regulatory, confidential information, or medical issues.
DISCLAIMER
Millennium does not endorse any user or associated products and services of any social media user that interacts with our profiles. Millennium may link to an external website for interest or convenience. Millennium claims no responsibility for the content of sites over which we have no control, and are not liable for any damages or injury arising from that content. Millennium reserves all rights relating to our social media profiles and properties, including discontinuing the Page, removing unwanted connections, responding to any questions or comments, and removing or modifying any content posted to the profile.